| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 203 companies in the Health Care Equipment & Supplies industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 11, 2025 | ITGR Integer Holdings Corp | Thomas Tommy P | VP, Corporate Controller | Sell | 884 | $70.15 | $62,012.60 | -19.7% | +22.4% | - | |
| Nov 11, 2025 | STE Steris Plc | Zangerle John Adam51 | Sr. VP, Gen Counsel, And Sec. | Sell | 15,000 | $265.14 | $3,977,100.00 | -30.8% | -8.0% | - | |
| Nov 11, 2025 | ICUI Icu Medical Inc/de | Sanzone Virginia Ruth64 | VP, General Counsel | Sell | 930 | $142.35 | $132,380.85 | -14.6% | +6.0% | - | |
| Nov 11, 2025 | AORT Artivion, Inc. | Holloway Jean F49 | SVP, General Counsel | Sell | 12,960 | $45.82 | $593,872.24 | -3.7% | -15.5% | - | |
| Nov 11, 2025 | AXGN Axogen, Inc. | Burke William P. Mr.56 | Director | Sell | 22,818 | $24.01 | $547,888.91 | -99.1% | +38.7% | - | |
| Nov 10, 2025 | IRTC Irhythm Holdings, Inc. | Talwalkar Abhijit Y56 | Director | Sell | 5,312 | $174.13 | $924,961.65 | -3.9% | -15.8% | - | |
| Nov 10, 2025 | PEN Penumbra Inc | Roberts Johanna54 | EVP, Gen. Counsel &Secretary | Sell | 600 | $266.98 | $160,188.63 | -0.1% | +25.3% | - | |
| Nov 10, 2025 | EW Edwards Lifesciences Corp | Lippis Daniel J.62 | Cvp, Japac | Sell | 1,020 | $82.55 | $84,196.00 | -4.4% | -8.7% | - | |
| Nov 10, 2025 | DXCM Dexcom Inc | Leach Jacob Steven55 | President &COO | Buy | 18,200 | $55.04 | $1,001,701.90 | +2.8% | +27.9% | - | |
| Nov 10, 2025 | IRMD Iradimed Corp | Glenn John | Chief Financial Officer | Sell | 10,651 | $84.51 | $900,161.81 | -81.0% | +11.5% | - | |
| Nov 10, 2025 | EW Edwards Lifesciences Corp | Ullem Scott B.65 | Cvp, Chief Financial Officer | Sell | 13,000 | $83.08 | $1,080,093.43 | -12.6% | -8.7% | - | |
| Nov 10, 2025 | AORT Artivion, Inc. | Davis John E | Chief Commercial Officer | Sell | 3,373 | $44.62 | $150,499.89 | -1.6% | -11.9% | - | |
| Nov 10, 2025 | AORT Artivion, Inc. | MacKin James P53 | President &CEO | Sell | 17,580 | $44.62 | $784,402.02 | -2.1% | -11.9% | - | |
| Nov 10, 2025 | SERA Sera Prognostics, Inc. | Boniface John J.56 | Chief Scientific Officer | Sell | 7,767 | $2.62 | $20,349.54 | -4.9% | +5.1% | - | |
| Nov 10, 2025 | INCY Incyte Corp | Hoppenot Herve | Director | Sell | 187,500 | $105.46 | $19,773,750.00 | -36.3% | +2.9% | - | |
| Nov 10, 2025 | SERA Sera Prognostics, Inc. | Lindgardt Zhenya81 | Chief Executive Officer | Sell | 11,594 | $2.62 | $30,376.28 | -1.4% | +5.1% | - | |
| Nov 10, 2025 | EKSO Ekso Bionics Holdings, Inc. | Jones Jason C64 | Chief Operating Officer | Sell | 9,723 | $4.80 | $46,670.40 | -26.3% | +99.6% | - | |
| Nov 10, 2025 | EKSO Ekso Bionics Holdings, Inc. | Davis Scott G.61 | CEO | Sell | 23,315 | $4.80 | $111,912.00 | -22.8% | +99.6% | - | |
| Nov 10, 2025 | SERA Sera Prognostics, Inc. | Aerts Austin82 | Chief Financial Officer | Sell | 6,351 | $2.62 | $16,639.62 | -2.2% | +5.1% | - | |
| Nov 10, 2025 | SERA Sera Prognostics, Inc. | Kearney Paul81 | Chief Data Officer | Sell | 7,073 | $2.62 | $18,531.26 | -4.0% | +5.1% | - | |
| Nov 10, 2025 | SERA Sera Prognostics, Inc. | Harrison Robert Gardner76 | Chief Information Officer | Sell | 6,528 | $2.62 | $17,103.36 | -6.8% | +5.1% | - | |
| Nov 10, 2025 | EKSO Ekso Bionics Holdings, Inc. | Wong Jerome55 | Chief Financial Officer | Sell | 11,288 | $4.80 | $54,182.40 | -30.3% | +99.6% | - | |
| Nov 10, 2025 | ESTA Establishment Labs Holdings Inc. | Jw Asset Management, LLC65 | 10% Owner | Sell | 11,000 | $67.07 | $737,770.00 | -0.4% | +2.7% | - | |
| Nov 10, 2025 | HAE Haemonetics Corp | Kroll Mark W | Director | Buy | 1,400 | $70.56 | $98,784.00 | +6.0% | -18.1% | - | |
| Nov 10, 2025 | SERA Sera Prognostics, Inc. | Jackson Benjamin83 | General Counsel | Sell | 7,059 | $2.62 | $18,494.58 | -5.6% | +5.1% | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.